PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.226
EU - Europa 9.275
AS - Asia 1.982
AF - Africa 52
SA - Sud America 50
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 21
Totale 24.643
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.156
IT - Italia 2.516
IE - Irlanda 2.154
GB - Regno Unito 1.837
SE - Svezia 836
CN - Cina 743
DE - Germania 730
HK - Hong Kong 496
UA - Ucraina 345
FR - Francia 212
TR - Turchia 208
FI - Finlandia 203
BG - Bulgaria 165
IN - India 138
VN - Vietnam 119
CA - Canada 64
JP - Giappone 55
BE - Belgio 48
MY - Malesia 37
TW - Taiwan 37
AU - Australia 35
IQ - Iraq 35
RU - Federazione Russa 35
ES - Italia 31
EG - Egitto 27
IR - Iran 24
KR - Corea 22
NL - Olanda 21
BR - Brasile 19
EU - Europa 17
CH - Svizzera 15
PL - Polonia 15
RO - Romania 15
CL - Cile 14
SG - Singapore 14
PK - Pakistan 13
CZ - Repubblica Ceca 12
GR - Grecia 11
AL - Albania 9
ID - Indonesia 9
DK - Danimarca 8
ET - Etiopia 8
PH - Filippine 8
SI - Slovenia 8
HU - Ungheria 7
MK - Macedonia 7
AR - Argentina 6
MT - Malta 6
IL - Israele 5
PT - Portogallo 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
KE - Kenya 4
LV - Lettonia 4
NO - Norvegia 4
SA - Arabia Saudita 4
TZ - Tanzania 4
AP - ???statistics.table.value.countryCode.AP??? 3
BD - Bangladesh 3
CR - Costa Rica 3
EC - Ecuador 3
HR - Croazia 3
IS - Islanda 3
MX - Messico 3
AT - Austria 2
BO - Bolivia 2
MA - Marocco 2
MD - Moldavia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
LB - Libano 1
MC - Monaco 1
ME - Montenegro 1
MZ - Mozambico 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
ZA - Sudafrica 1
ZM - Zambia 1
Totale 24.643
Salva come PNG Salva come JPEG
Città #
Dublin 2.149
Fairfield 1.752
Chandler 1.433
Southend 1.325
Ashburn 1.059
Woodbridge 1.011
Houston 760
Dearborn 735
Seattle 700
Nyköping 668
Ann Arbor 666
Jacksonville 601
Wilmington 601
Cambridge 534
Hong Kong 481
Beijing 306
New York 263
Modena 251
Milan 191
San Diego 178
Princeton 174
Sofia 164
Eugene 141
Helsinki 138
Rome 135
Izmir 129
Dong Ket 112
Shanghai 106
Redwood City 104
Fremont 100
Bologna 92
Bremen 77
London 72
Falls Church 67
Norwalk 43
Brussels 41
Boardman 40
San Giuliano Milanese 35
Enfield 32
Guangzhou 32
Parma 32
Nanjing 31
Turin 31
Des Moines 30
Reggio Emilia 30
Phoenix 29
Ottawa 28
Hefei 26
Naples 23
Padova 23
Baghdad 22
Lansdale 22
Palermo 22
Asyut 21
Paris 21
San Mateo 21
Kunming 19
Tokyo 17
Catania 15
Florence 15
Fulham 15
Toronto 15
Banqiao 14
Chiswick 14
Absecon 13
Frankfurt am Main 13
Hyderabad 13
Verona 13
Brescia 12
Chicago 12
Nanchang 12
Napoli 12
Pisa 12
Rimini 12
Taipei 12
Vicenza 12
Bangalore 11
Genoa 11
Mumbai 10
Perugia 10
Piacenza 10
Sassuolo 10
Stockholm 10
Sydney 10
Wuhan 10
Athens 9
Bari 9
Brooklyn 9
Washington 9
Caprarola 8
Castelvetrano 8
Duncan 8
Falkenstein 8
Jinan 8
Kilburn 8
Madrid 8
Monmouth Junction 8
Monza 8
Reggio Nell'emilia 8
San Marco 8
Totale 18.398
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 434
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 354
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 282
GD2 expression in breast cancer. 280
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 272
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 271
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 260
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 259
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 250
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 250
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 241
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 237
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 237
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 234
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 230
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. 229
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 225
Oxford Manuale di Medicina Clinica 222
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 213
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 212
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 212
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 212
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 210
Tumor Stroma Manipulation By MSC 210
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 206
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 206
Abemaciclib: eventi avversi e riduzione di dose. 205
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 204
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 195
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 194
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 192
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 189
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 188
Immune characterization of breast cancer metastases: prognostic implications. 187
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 185
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 184
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 184
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 184
Achievements and unmet needs in the management of advanced ovarian cancer 182
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 181
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 180
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 180
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 180
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 179
Timing for starting second line therapy in recurrent ovarian cancer. 178
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 178
Prognostic Factors for Breast Cancer: an Immunomorphological Update 177
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 176
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 175
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 173
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 169
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 169
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 168
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 168
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 168
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 166
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 166
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 165
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 164
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 163
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 163
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 162
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 160
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 158
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 157
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 154
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 154
Breast Location for De Novo Extramedullary Myeloid Sarcoma 154
Preoperative letrozole plus lapatinib/placebo for HR+/HER2 negative operable breast cancer: biomarker analyses of the randomized phase II LET-LOB study 150
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 148
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 148
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 147
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 146
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 145
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 144
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 144
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 144
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 142
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 140
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 140
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 140
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 138
Lapatinib and renal impairment: a case report 137
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 137
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). 136
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 134
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 133
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 132
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 132
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. 128
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 128
Tumor infiltrating lymphocytes and correlation with pCR in ther CHERLOB study 125
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 125
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 124
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 124
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 121
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. 121
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 121
Varicella zoster virus reactivation in patients with breast cancer and multiple myeloma after autologous stem cell transplantation 120
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 120
Totale 18.120
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.390
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.193 0 0 0 0 0 0 0 0 0 167 439 587
2019/20204.380 312 215 189 284 492 685 831 386 385 178 273 150
2020/20214.274 426 201 259 330 484 369 364 456 266 465 345 309
2021/20223.347 133 383 286 129 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20242.885 179 203 239 292 496 314 342 569 150 101 0 0
Totale 25.006